Cargando…
Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study
AIM: Cirrhosis is a leading cause of death worldwide, yet there are no well‐established risk stratifying tools for lethal complications, including hepatocellular carcinoma (HCC). Patients with liver cirrhosis undergo routine endoscopic surveillance, providing ready access to duodenal aspirate sample...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334634/ https://www.ncbi.nlm.nih.gov/pubmed/29923681 http://dx.doi.org/10.1111/hepr.13207 |
_version_ | 1783387760773562368 |
---|---|
author | Jacobs, Jonathan P. Dong, Tien S. Agopian, Vatche Lagishetty, Venu Sundaram, Vinay Noureddin, Mazen Ayoub, Walid S. Durazo, Francisco Benhammou, Jihane Enayati, Pedram Elashoff, David Goodman, Marc T. Pisegna, Joseph Hussain, Shehnaz |
author_facet | Jacobs, Jonathan P. Dong, Tien S. Agopian, Vatche Lagishetty, Venu Sundaram, Vinay Noureddin, Mazen Ayoub, Walid S. Durazo, Francisco Benhammou, Jihane Enayati, Pedram Elashoff, David Goodman, Marc T. Pisegna, Joseph Hussain, Shehnaz |
author_sort | Jacobs, Jonathan P. |
collection | PubMed |
description | AIM: Cirrhosis is a leading cause of death worldwide, yet there are no well‐established risk stratifying tools for lethal complications, including hepatocellular carcinoma (HCC). Patients with liver cirrhosis undergo routine endoscopic surveillance, providing ready access to duodenal aspirate samples that could be a source for identifying novel biomarkers. The aim of this study was to characterize the microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis to assess the feasibility of developing biomarkers for HCC risk stratification. METHODS: Thirty patients with liver cirrhosis were enrolled in the Microbiome, Microbial Markers, and Liver Disease study between May 2015 and March 2017. Detailed clinical and epidemiological data were collected at baseline and at 6‐monthly follow‐up visits. Duodenal aspirate fluid was collected at baseline for microbial characterization using 16S ribosomal RNA sequencing and bile acid quantification using mass spectroscopy. RESULTS: Alcohol‐related cirrhosis was associated with reductions in the Bacteroidetes phylum, particularly Prevotella (13‐fold reduction), and expansion of Staphylococcus (13‐fold increase), compared to hepatitis C virus‐related cirrhosis. Participants with hepatic encephalopathy (HE) had less microbial diversity compared to patients without HE (P < 0.05), and were characterized by expansion of Mycobacterium (45‐fold increase) and Gram‐positive cocci including Granulicatella (3.1‐fold increase), unclassified Planococcaceae (3.3‐fold increase), and unclassified Streptococcaceae (4.5‐fold increase). Non‐Hispanic White patients had reduced microbial richness (P < 0.01) and diversity (P < 0.05), and increased levels of conjugated ursodeoxycholic acid (glycoursodeoxycholic acid and tauroursodeoxycholic acid, P < 0.05) compared to Hispanic patients. CONCLUSION: Microbial profiles of duodenal aspirates differed by cirrhosis etiology, HE, and Hispanic ethnicity. |
format | Online Article Text |
id | pubmed-6334634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63346342019-01-23 Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study Jacobs, Jonathan P. Dong, Tien S. Agopian, Vatche Lagishetty, Venu Sundaram, Vinay Noureddin, Mazen Ayoub, Walid S. Durazo, Francisco Benhammou, Jihane Enayati, Pedram Elashoff, David Goodman, Marc T. Pisegna, Joseph Hussain, Shehnaz Hepatol Res Original Articles AIM: Cirrhosis is a leading cause of death worldwide, yet there are no well‐established risk stratifying tools for lethal complications, including hepatocellular carcinoma (HCC). Patients with liver cirrhosis undergo routine endoscopic surveillance, providing ready access to duodenal aspirate samples that could be a source for identifying novel biomarkers. The aim of this study was to characterize the microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis to assess the feasibility of developing biomarkers for HCC risk stratification. METHODS: Thirty patients with liver cirrhosis were enrolled in the Microbiome, Microbial Markers, and Liver Disease study between May 2015 and March 2017. Detailed clinical and epidemiological data were collected at baseline and at 6‐monthly follow‐up visits. Duodenal aspirate fluid was collected at baseline for microbial characterization using 16S ribosomal RNA sequencing and bile acid quantification using mass spectroscopy. RESULTS: Alcohol‐related cirrhosis was associated with reductions in the Bacteroidetes phylum, particularly Prevotella (13‐fold reduction), and expansion of Staphylococcus (13‐fold increase), compared to hepatitis C virus‐related cirrhosis. Participants with hepatic encephalopathy (HE) had less microbial diversity compared to patients without HE (P < 0.05), and were characterized by expansion of Mycobacterium (45‐fold increase) and Gram‐positive cocci including Granulicatella (3.1‐fold increase), unclassified Planococcaceae (3.3‐fold increase), and unclassified Streptococcaceae (4.5‐fold increase). Non‐Hispanic White patients had reduced microbial richness (P < 0.01) and diversity (P < 0.05), and increased levels of conjugated ursodeoxycholic acid (glycoursodeoxycholic acid and tauroursodeoxycholic acid, P < 0.05) compared to Hispanic patients. CONCLUSION: Microbial profiles of duodenal aspirates differed by cirrhosis etiology, HE, and Hispanic ethnicity. John Wiley and Sons Inc. 2018-07-30 2018-12 /pmc/articles/PMC6334634/ /pubmed/29923681 http://dx.doi.org/10.1111/hepr.13207 Text en © 2018 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Jacobs, Jonathan P. Dong, Tien S. Agopian, Vatche Lagishetty, Venu Sundaram, Vinay Noureddin, Mazen Ayoub, Walid S. Durazo, Francisco Benhammou, Jihane Enayati, Pedram Elashoff, David Goodman, Marc T. Pisegna, Joseph Hussain, Shehnaz Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title | Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title_full | Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title_fullStr | Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title_full_unstemmed | Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title_short | Microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: The Microbiome, Microbial Markers and Liver Disease Study |
title_sort | microbiome and bile acid profiles in duodenal aspirates from patients with liver cirrhosis: the microbiome, microbial markers and liver disease study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334634/ https://www.ncbi.nlm.nih.gov/pubmed/29923681 http://dx.doi.org/10.1111/hepr.13207 |
work_keys_str_mv | AT jacobsjonathanp microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT dongtiens microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT agopianvatche microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT lagishettyvenu microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT sundaramvinay microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT noureddinmazen microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT ayoubwalids microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT durazofrancisco microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT benhammoujihane microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT enayatipedram microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT elashoffdavid microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT goodmanmarct microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT pisegnajoseph microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy AT hussainshehnaz microbiomeandbileacidprofilesinduodenalaspiratesfrompatientswithlivercirrhosisthemicrobiomemicrobialmarkersandliverdiseasestudy |